Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLICEL LIFE SCIENCES INC.

(REPCF)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about REPLICEL LIFE SCIENCES INC.
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido
CI
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..
CI
2021RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.99892 million in..
CI
2021RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
2021REPLICEL LIFE SCIENCES : NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Fo..
PU
2021REPLICEL LIFE SCIENCES : Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study ..
PU
2021RepliCel Ships DermaPreciseTM Injector Prototypes and Consumables to Independent Labora..
PU
2021RepliCel's Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to..
PU
2021Testing progresses to next-phase; results lead to some component upgrades to ensure opt..
PU
2021RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
PU
2021Replicel Announces Dermaprecise Trademark for Dermal Injector Product Line
CI
2021RepliCel Announces Dermal Injector Update
PU
2021RepliCel Life Sciences Inc. Announces Dermal Injector Update
CI
2021REPLICEL LIFE SCIENCES : Files Notice of Arbitration against Shiseido Company to Resolve i..
PU
2021REPLICEL LIFE SCIENCES : Files Notice of Arbitration against Shiseido Company to Resolve i..
PU
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Appoints One of Japan's Foremost Regenerative Medicine Industry B..
AQ
2021REPLICEL LIFE SCIENCES : Kunihiko Suzuki, one of the leading pioneers in Japan's emerging ..
PU
2021REPLICEL LIFE SCIENCES : News Release dated September 16, 2021 - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Appoints One of Japan's Foremost Regenerative Medicine Industry B..
PU
2021RepliCel Life Sciences Inc. Appoints Kunihiko Suzuki as Senior Strategic Advisor to Its..
CI
2021REPLICEL LIFE SCIENCES : and University of Victoria Collaboration Leads to Bioengineering ..
PU
2021RepliCel Life Sciences Inc. and University of Victoria Collaboration Leads to Bioengine..
CI
2021Replicel Life Sciences Inc. Reports Earnings Results for the Second Quarter Ended June ..
CI
2021REPLICEL LIFE SCIENCES : Announces Closing of Debt Settlement (Form 6-K)
PU
2021REPLICEL LIFE SCIENCES : Clinical development of RepliCel's skin rejuvenation and tendon r..
PU
2021RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Ce..
CI
2021REPLICEL LIFE SCIENCES : Professor Tsukasa Kumai, member of the Japan's Olympic Committee ..
PU
2021REPLICEL LIFE SCIENCES : Targets for 2021 include dermal injector commercial launch, new p..
PU
2021REPLICEL LIFE SCIENCES : Announces Debt Settlement (Form 6-K)
PU
2021REPLICEL LIFE SCIENCES : Applies for Manufacturing Approval for Its Collagen and Tissue Re..
AQ
2021RepliCel Life Sciences Inc. Applies for Manufacturing Approval for its Collagen and Tis..
CI
2021REPLICEL LIFE SCIENCES : Adds Independent Director
PU
2021RepliCel Life Sciences Inc. Appoints Gary Boddington to the Board of Directors
CI
2021RepliCel Life Sciences Inc. announced that it has received $0.16152 million in funding
CI
2021REPLICEL LIFE SCIENCES : Announces Closing of Debt Settlement
AQ
2021RepliCel Life Sciences Inc. announced that it has received $0.111574 million in funding
CI
2021RepliCel Life Sciences Inc. announced that it expects to receive $0.111574 million in f..
CI
2021RepliCel Life Sciences Inc. Reports Earnings Results for the First quarter Ended March ..
CI
2021Replicel Life Sciences Inc. Receiveds the First Units of Its Dermal Injector and Is Nea..
CI
2021REPLICEL LIFE SCIENCES : Launches Testing of Dermal Injector Units
PU
2021REPLICEL LIFE SCIENCES : Launches Preparations for Second Skin Rejuvenation and Tendon Reg..
PU
2021RepliCel Announces Appointment of Akimichi Moritaas as Clinical Advisor
CI
2021Replicel Launches the Next Stage of A Research Project with The University of British C..
CI
2021REPLICEL LIFE SCIENCES : Launches the Next Stage of a Research Project with the University..
PU
2021Replicel Life Sciences Inc. Announces Record Year in Patents Granted
CI
2021REPLICEL LIFE SCIENCES : Announces Record Year in Patents Granted
PU
2021RepliCel Life Sciences Inc. Appoints Tsukasa Kumai as Clinical Advisor for the Developm..
CI
2021REPLICEL LIFE SCIENCES : Announces Appointment of Leading Sports Medicine Expert as Orthop..
PU
2021Replicel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
2021REPLICEL LIFE SCIENCES : Closes Second Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.492091 million in fund..
CI
2021REPLICEL BRIEF : Up 6.6% As Presents Its Technology Development and Commercialization Plan..
MT
2021REPLICEL BRIEF : Down More Than 8% As Closes First Tranche of Strategic Investment Commitm..
MT
2021REPLICEL BRIEF : CEO Says Targets for 2021 Include "Dermal Injector Commercial Launch, New..
MT
2021REPLICEL BRIEF : CEO Provides Corporate Update; Comes After Stock Jumped 26.5% on Friday
MT
2021RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.492091 million i..
CI
2020RepliCel Life Sciences Inc. Announces Restatement of Earnings Results for the Year Ende..
CI
2020Replicel Life Sciences Inc. Announces Resignation of Directors
CI
2020Replicel Life Sciences Inc. Reports Earnings Results for the Third Quarter Ended Septem..
CI
2020RepliCel Life Sciences Inc. Announces Distribution Partnership with Mainpointe Pharmace..
CI
2020REPLICEL LIFE SCIENCES : Up 17.5% As Details Binding Term Sheet for Strategic Investment, ..
MT
2020REPLICEL BRIEF : Up 17.5% As Details Binding Term Sheet For Strategic Investment and U.S. ..
MT
2020REPLICEL LIFE SCIENCES : Announces a Binding Term Sheet For Strategic Investment and U.S. ..
AQ
2020RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership
GL
2020RepliCel Life Sciences Inc. announced that it expects to receive CAD 2.7 million in fun..
CI
2020REPLICEL LIFE SCIENCES : Q3 2020 Management Update
AQ
2020RepliCel Life Sciences Inc. Postpones Filing of Interim Financial Statements and MD&A D..
CI
2020REPLICEL LIFE SCIENCES : Announces Closing of Debt Settlement and Additional Debt Settleme..
AQ
2020RepliCel Life Sciences Inc. announced that it has received CAD 0.155645 million in fund..
CI
2020RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.155645 million i..
CI
2020Replicel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
2020Replicel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
1  2Next
Upcoming event on REPLICEL LIFE SCIENCES INC.
05/04/22